ライフサイエンスコーパス: cryptococcal meningitis

1 gnificantly attenuated in an animal model of cryptococcal meningitis.

2 e no longer pathogenic in an animal model of cryptococcal meningitis.

3 , but their use is untested in patients with cryptococcal meningitis.

4 mulating factor (GM-CSF) autoantibodies with cryptococcal meningitis.

5 of people who are developing and dying from cryptococcal meningitis.

6 important contributor to virulence in human cryptococcal meningitis.

7 be considered for point-of-care diagnosis of cryptococcal meningitis.

8 sease severity and outcome in HIV-associated cryptococcal meningitis.

9 rebrospinal fluid samples from patients with cryptococcal meningitis.

10 tosine as first-line induction treatment for cryptococcal meningitis.

11 to safe and effective antifungal therapy for cryptococcal meningitis.

12 d with improved survival among patients with cryptococcal meningitis.

13 lus 5-FC for the treatment of HIV-associated cryptococcal meningitis.

14 One patient developed Cryptococcal meningitis.

15 s to promote increased ICP in a rat model of cryptococcal meningitis.

16 acquired immunodeficiency syndrome and acute cryptococcal meningitis.

17 ain was also avirulent in an animal model of cryptococcal meningitis.

18 ormans var. grubii is the causative agent of cryptococcal meningitis, a significant source of mortali

19 Cryptococcal meningitis accounts for 20 to 25% of acquir

20 nal fluid (CSF) samples for the diagnosis of cryptococcal meningitis against that of existing diagnos

21 creased relative rate of 0.49 (P = 0.06) for cryptococcal meningitis and a decreased relative rate of

22 val of HIV-infected persons with symptomatic cryptococcal meningitis and asymptomatic, subclinical cr

23 e in the treatment of fungal infections like cryptococcal meningitis and C. albicans infections.

24 mouse IgG1 currently in clinical trials for cryptococcal meningitis and for the design of antibody t

25 ed adults in Uganda and South Africa who had cryptococcal meningitis and had not previously received

26 body screening in four current patients with cryptococcal meningitis and identified and tested 103 ar

27 nvasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida

28 mma 1b holds promise for patients with acute cryptococcal meningitis and warrants further study.

29 mortality among patients with HIV-associated cryptococcal meningitis and was associated with more adv

30 meningitis and sepsis), fungal (for example, cryptococcal meningitis) and parasitic (for example, mal

31 ncidences of secondary P. carinii pneumonia, cryptococcal meningitis, and herpes zoster have declined

32 colony-stimulating factor autoantibodies and cryptococcal meningitis; anti-interleukin (IL)-6 autoant

33 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis are poorly defined.

34 Cryptococcal meningitis associated with human immunodefi

35 measured in 44 patients with HIV-associated cryptococcal meningitis at baseline and during follow-up

36 lucytosine) is the recommended treatment for cryptococcal meningitis but has not been shown to reduce

37 gressive multifocal leucoencephalopathy, and cryptococcal meningitis) but also the AIDS dementia comp

38 is an important determinant of mortality in cryptococcal meningitis, but its use in aiding clinical

39 an Africa accounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95

40 In the United States, cryptococcal meningitis causes approximately 3400 hospit

41 lasma CRAG titers >1:640, 96% (27 of 28) had cryptococcal meningitis (cerebrospinal fluid CRAG-positi

42 (25[OH]D) were measured in 150 patients with cryptococcal meningitis (CM) and 150 HIV-infected contro

43 ) or did not (HIV-infected controls) develop cryptococcal meningitis (CM) and HIV-uninfected persons

44 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) and is lower in patients on

45 Ocular complications in cryptococcal meningitis (CM) are commonly attributed to

46 ated to raise intracranial pressure (ICP) in cryptococcal meningitis (CM) by mechanical obstruction o

47 y virus (HIV)-infected patients with treated cryptococcal meningitis (CM) commencing combination anti

48 human immunodeficiency virus/AIDS-associated cryptococcal meningitis (CM) frequently experience clini

49 Cryptococcal meningitis (CM) is a leading cause of death

50 Cryptococcal meningitis (CM) is a leading cause of HIV-a

51 Cryptococcal meningitis (CM) is a major cause of death a

52 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) is characterized by high fu

53 Cryptococcal meningitis (CM) is one of the most common c

54 study to determine the national incidence of cryptococcal meningitis (CM), and describe characteristi

55 Cryptococcal meningitis (CM)-related immune reconstituti

56 Cryptococcal meningitis (CM)-related mortality may be pr

57 patient, who defaulted from care, died from cryptococcal meningitis (CM).

58 e cerebrospinal fluid (CSF) of patients with cryptococcal meningitis contains high levels of the chem

59 with 10 liver transplant recipients in whom cryptococcal meningitis developed after liver transplant

60 iagnosis prompted screening of patients with cryptococcal meningitis for anticytokine autoantibodies.

61 0 (95% CI 150 600-282 400) incident cases of cryptococcal meningitis globally in 2014.

62 One patient with cryptococcal meningitis had autoantibodies only against

63 No persons with cryptococcal meningitis had negative fingersticks.

64 cquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mo

65 Cryptococcal meningitis has been described in immunocomp

66 ubacute sclerosing panencephalitis (SSPE) or cryptococcal meningitis have been shown to represent Ab

67 ubacute sclerosing panencephalitis (SSPE) or cryptococcal meningitis have been shown to represent Ab

68 Toxoplasmosis, cryptococcal meningitis, herpes zoster, the wasting synd

69 rapy have been proposed for the treatment of cryptococcal meningitis in AIDS patients.

70 r a trial on the treatment of HIV-associated cryptococcal meningitis in Mbarara, Uganda.

71 2-year-old woman who received a diagnosis of cryptococcal meningitis in November 1998.

72 antibodies are associated with some cases of cryptococcal meningitis in otherwise immunocompetent pat

73 Fluconazole is effective in the therapy of cryptococcal meningitis in patients with AIDS.

74 p, open-label trial of induction therapy for cryptococcal meningitis in patients with human immunodef

75 Patients with cryptococcal meningitis in sub-Saharan Africa frequently

76 recruited adult patients with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia,

77 Early ART initiation in cryptococcal meningitis increased CSF cellular infiltrat

78 Cryptococcal meningitis is a fungal infection, caused by

79 Cryptococcal meningitis is a metric of HIV treatment pro

80 We conclude that cryptococcal meningitis is a rare complication in liver

81 HIV-associated cryptococcal meningitis is associated with an estimated

82 Cryptococcal meningitis is the leading cause of adult me

83 Cryptococcal meningitis is the most common cause of adul

84 Cryptococcal meningitis is the most frequent cause of me

85 Cryptococcal meningitis occurs in 6 to 8% of human immun

86 Antifungal treatment for cryptococcal meningitis relies on three old, off-patent

87 Cryptococcal meningitis remains a significant cause of d

88 n ART should be initiated after diagnosis of cryptococcal meningitis remains unanswered.

89 r antiretroviral therapy (ART) initiation in cryptococcal meningitis resulted in higher mortality com

90 Altered mental status in cryptococcal meningitis results in poorer survival, but

91 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis, screened for the Cryptococcal O

92 Only the incidences of cryptococcal meningitis, secondary P. carinii pneumonia,

93 lence tests with rabbit and murine models of cryptococcal meningitis showed that the serotype A conge

94 ccus gattii isolated from serial episodes of cryptococcal meningitis that were separated by at least

95 For the initial treatment of AIDS-associated cryptococcal meningitis, the use of higher-dose amphoter

96 In this model of cryptococcal meningitis, there was evidence of a dose re

97 s the most attractive treatment strategy for cryptococcal meningitis, though the rising price may be

98 bacterial pneumonia, two tuberculosis, five cryptococcal meningitis, three had other infections, and

99 ents with a first episode of AIDS-associated cryptococcal meningitis to treatment with higher-dose am

100 In an animal model of cryptococcal meningitis, topoisomerase I regulation was

101 and 189 ART-naive Ugandans with symptomatic cryptococcal meningitis treated with amphotericin (CM co

102 rring ART for 5 weeks after the diagnosis of cryptococcal meningitis was associated with significantl

103 Globally, cryptococcal meningitis was responsible for 15% of AIDS-

104 One patient with cryptococcal meningitis was successfully treated.

105 Patients with a first episode of cryptococcal meningitis were enrolled, and their immune

106 duals assessed, 172 HIV-infected adults with cryptococcal meningitis were enrolled.

107 Annual global deaths from cryptococcal meningitis were estimated at 181 100 (95% C

108 In this study, rabbits with experimental cryptococcal meningitis were given fluconazole at low, i

109 ntiretroviral naive patients presenting with cryptococcal meningitis were randomized to 4 treatment a

110 t this hypothesis, we used a murine model of cryptococcal meningitis whereby cryptococci are introduc

111 tibodies in an otherwise healthy female with cryptococcal meningitis who later developed pulmonary al

112 , we recruited HIV-infected individuals with cryptococcal meningitis who presented to Mulago Hospital

113 mmunodeficiency virus-infected patients with cryptococcal meningitis who received antifungal therapy

114 iciency virus-infected patients with treated cryptococcal meningitis who start combination antiretrov

115 identified seven HIV-negative patients with cryptococcal meningitis who tested positive for high-tit

116 tive participants, 138 (93%) had evidence of cryptococcal meningitis with a positive CSF CRAG.

117 We review the antifungal drugs used to treat cryptococcal meningitis with respect to clinical effecti

118 Nine CSF samples from patients with cryptococcal meningitis yielded positive results using b